NDA 022064 · Chattem Sanofi
Xyzal
Levocetirizine Dihydrochloride · Oral
Priority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
May 25, 2007
Approved uses
2
Original approval plus efficacy supplements
Registered trials
77
22 Phase 3, 4 recruiting
FAERS reports
18,341
9,290 serious, 966 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 22, 2025.
XYZAL is a histamine H 1 -receptor antagonist indicated for: The relief of symptoms associated with perennial allergic rhinitis ( 1.1 ) The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria ( 1.2 ) 1.1 Perennial Allergic Rhinitis XYZAL is indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 months to 2 years of age. 1.2 Chronic Idiopathic Urticaria XYZAL is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older.
Mechanism: Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H 1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H 1 -receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L vs . 6 nmol/L, respectively). The clinical relevance of this finding is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 21, 2009 Supplement 17 · Efficacy · priority review LabelLetter
- May 25, 2007 Original approval · Type 5 - New Formulation or New Manufacturer · priority review ReviewSummary ReviewPediatric Written Request
1 products under this application
- XYZAL · LEVOCETIRIZINE DIHYDROCHLORIDE 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Levocetirizine Dihydrochloride" as an intervention, any sponsor and status, largest first.
- CUTE (Chronic Urticaria Treatment Evaluation)Pivotal-lookingCompleted
UCB PharmaUCB
NCT00264303 · 886 participants · Start Dec 2005 · Primary completion Jan 2007
Drug: Levocetirizine; Desloratadine · For: Chronic Idiopathic Urticaria
Sites: Bruges, Belgium; Brussels, Belgium; Liège, Belgium · 80 sites in all
- LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)Pivotal-lookingCompleted
UCB PharmaUCB
NCT00160589 · 729 participants · Start Apr 2005 · Primary completion Sep 2005
Drug: Levocetirizine · For: Rhinitis, Allergic, Perennial
- A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic RhinitisPivotal-lookingCompleted
UCB PharmaUCB
NCT00621959 · 596 participants · Start Mar 2008 · Primary completion Jun 2008
Drug: levocetirizine dihydrochloride; placebo · For: Seasonal Allergic Rhinitis
Sites: Scottsdale, Arizona; Hot Springs, Arkansas; Little Rock, Arkansas · 26 sites in all
- A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic RhinitisPivotal-lookingCompleted
UCB PharmaUCB
NCT00653224 · 580 participants · Start Apr 2008 · Primary completion Jul 2008
Drug: levocetirizine dihydrochloride; placebo · For: Seasonal Allergic Rhinitis
Sites: Tucson, Arizona; Los Angeles, California; Sacramento, California · 38 sites in all
- Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive SubjectsPivotal-lookingCompleted
UCB PharmaUCB
NCT00544388 · 570 participants · Start Apr 2004 · Primary completion Jul 2004
Drug: levocetirizine dihydrochloride · For: Rhinitis, Allergic, Seasonal
- A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed PollenPivotal-lookingCompleted
UCB PharmaUCB
NCT00291642 · 551 participants · Start Jan 1, 2006 · Primary completion Apr 1, 2006
Drug: Placebo drops; Placebo tablets matching to levocetirizine and 5 more · For: Rhinitis; Allergic; Seasonal
Sites: Kingston, Canada
- Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic UrticariaPivotal-lookingCompleted
Faes Farma, S.A.Industry
NCT00421109 · 522 participants · Start Jul 2006 · Primary completion Jul 2007
Drug: Bilastine; Levocetirizine and 1 more · For: Urticaria
Sites: Buenos Aires, Argentina; Mar Del Plata / Buenos Aires, Argentina; Rosario - Santa Fe, Argentina · 50 sites in all
- Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)Pivotal-lookingCompleted
NCT00152464 · 514 participants · Start Mar 20, 2002 · Primary completion Mar 15, 2006
Drug: Placebo; Levocetirizine · For: Dermatitis, Atopic
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,535
- fatigue1,340
- headache1,232
- pruritus1,204
- nausea1,069
- dyspnoea1,055
- diarrhoea990
- somnolence926
- dizziness823
- arthralgia781
- cough764
- rash758
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 10 |
| 2006 | 6 |
| 2007 | 25 |
| 2008 | 161 |
| 2009 | 238 |
| 2010 | 262 |
| 2011 | 438 |
| 2012 | 576 |
| 2013 | 396 |
| 2014 | 387 |
| 2015 | 554 |
| 2016 | 828 |
| 2017 | 814 |
| 2018 | 977 |
| 2019 | 1,693 |
| 2020 | 1,545 |
| 2021 | 1,240 |
| 2022 | 1,544 |
| 2023 | 1,669 |
| 2024 | 1,797 |
| 2025 | 1,800 |
| 2026 | 1,376 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bioequivalence of Levocetirizine Hydrochloride Granules (Kangzhitai) in Healthy Subjects.
Xiang H, Yang G, Tan H · Altern Ther Health Med 2023 · Randomized Controlled Trial
- Efficacy of levocetirizine compared with montelukast in subjects with ragweed-induced seasonal allergic rhinitis in the Environmental Exposure Unit.
Day JH, Briscoe MP, Ratz JD · Allergy Asthma Proc 2008 · Comparative Study, Randomized Controlled Trial
- Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis.
Barnes ML, Ward JH, Fardon TC, et al. · Clin Exp Allergy 2006 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Formulation and evaluation of taste-masked levocetirizine dihydrochloride orally disintegrating tablets.
Devireddy SR, Gonugunta CS, Veerareddy PR · PDA J Pharm Sci Technol 2009 · Comparative Study, Controlled Clinical Trial
- Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma.
Lee DK, Bates CE, Currie GP, et al. · J Allergy Clin Immunol 2003 · Clinical Trial, Comparative Study
- Randomized double-blind study of prophylactic treatment with an antihistamine for seasonal allergic rhinitis.
Yonekura S, Okamoto Y, Yamamoto H, et al. · Int Arch Allergy Immunol 2013 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Chattem Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.